The ‘Dual‐Pathway’ Strategy After Acute Coronary Syndrome: Rivaroxaban and Anti‐platelet Agents in the ATLAS ACS 2‐TIMI 51 Trial

This article is protected by copyright. All rights reserved.

Source: Cardiovascular Therapeutics - June 1, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Unsolicited Review Source Type: research